RT Journal Article
SR Electronic
T1 Semaglutide is non-inferior to placebo for cardiovascular outcomes in patients with type 2 diabetes
JF Evidence Based Medicine
JO Evid Based Med
FD BMJ Publishing Group Ltd
SP ebmed-2016-110652
DO 10.1136/ebmed-2016-110652
A1 Denise Campbell-Scherer
YR 2017
UL http://ebm.bmj.com/content/early/2017/03/07/ebmed-2016-110652.abstract
AB